Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Mydecine's research agreement with the University of Alberta is a key stepping-stone in expediting its psilocybin-based drug development research.
Mydecine announces research agreement with a leading pharmacology research institution.
Champignon Brands is proposing changing its corporate name to Apotheosis Scientific Ltd, and announces a planned spin-off its consumer packaged goods (CPG) division.
With the closing of its second tranche, Red Light Holland has now raised $3,830,529 in its current private placement.
Greenstar Biosciences is entering the psychedelics space via its acquisition of Eleusian Biosciences Corp.
New Wave Holdings Corp has added a recognized expert in psychedelic medicine to the company's Advisory Board.
Field Trip Psychedelics has just announced a letter of intent to go public via RTO.
Field Trip Psychedelics is planning to go public via a "three-cornered" RTO.
MindMed is adding to its clinical trials on psychedelics with a Phase 1 collaboration aimed at ayahuasca research.
Mydecine is acquiring the Digital Telehealth Platform of Mindleap Health Inc in a cash and shares deal.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now